Table 3.
Analysis of mutation profile of newly characterized SARS-CoV-2 isolates at baseline and during therapy of selected patients
| Patient number | Collection date | VOC | S gene | ORF1ab | E | M | ORF7a | N | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AF > 90% | AF < 90% | AF > 90% | AF < 90% | AF > 90% | AF > 90% | AF < 90% | AF > 90% | |||
| 1 | 2021–06-03 | B.1.1.7 | L822F | P1950L,A5376V, K5784R | V70L | P34L | P279Q | |||
| 2021–06-21 | B.1.1.7 |
Q493R, L822F |
P1950L,A5376V, K5784R | V70L | P34L | P279Q | ||||
| 2021–07-06 | B.1.1.7 |
Q493R, L822F |
A243V (61%), L938F (47%) | P1950L,A5376V, K5784R | V70L | P34L | P279Q | |||
| 2021–07-12 | B.1.1.7 |
Q493R, L822F |
A243V (25%), G446V (42%), L938F (38%) | P1950L,A5376V, K5784R | V70L | P34L | P279Q | |||
| 2021–07-19 | B.1.1.7 |
G446V, Q493R, L822F |
R102I (64%) R246I (27%), E484Q (62%) |
P1950L,A5376V, K5784R | V62F (28%) | V70L | P34L | P279Q | ||
| 2021–07-26 | B.1.1.7 |
R102I, D215H, G446V, E484Q, Q493R, L822F |
P1950L,A5376V, K5784R | V70L | P34L | P279Q | ||||
| 2021–08-04 | B.1.1.7 |
R102I, D215H, G446V, E484Q, Q493R, L822F |
A67S (21%), G252V (69%), T573I (26%) | P1950L,A5376V, K5784R | V70L | P34L | P279Q | |||
| 2 | 2022–01-21 | BA.1.1.529 (BA.1.17) | P1803S | |||||||
| 2022–02-12 | BA.1.1.529 (BA.1.17) | P1803S | ||||||||
| 3 | 2022–03-28 | BA.1.1.529 (BA.2.9) | A2279V, L6404I | |||||||
| 4 | 2022–05-26 | BA.1.1.529 (BA.2) | P34L (40%) | P326L (77%) | ||||||
| 5 | 2022–01-09 | BA.1.1.529 (BA.1.15) | P383L | |||||||
VOC Variant of concern; AF Allele frequency